Table of Contents
ISRN Cell Biology
Volume 2012 (2012), Article ID 587259, 11 pages
http://dx.doi.org/10.5402/2012/587259
Review Article

Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer

Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

Received 8 October 2012; Accepted 30 October 2012

Academic Editors: D. Arnoult and I. K. Koutna

Copyright © 2012 Dan G. Duda. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Antiangiogenic therapy for cancer has gone from an intriguing hypothesis in the 1970s to an accepted treatment approach for many cancer types. It has also become a standard of care for certain eye diseases. Yet, despite the use of molecularly targeted drugs with well defined targets, to date there are no biomarkers to guide the use of antiangiogenic therapy in patients. The mechanisms of action of these drugs are also being debated. This paper discusses some of the emerging biomarker candidates for this type of cancer therapy, which have provided mechanistic insight and might be useful in the future for optimizing cancer treatment.